Analyzing Longevity Health (NASDAQ:XAGE) & TransEnterix (OTCMKTS:TRXDW)

Insider & Institutional Ownership

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 8.2% of TransEnterix shares are held by institutional investors. 29.0% of Longevity Health shares are held by insiders. Comparatively, 3.1% of TransEnterix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Longevity Health and TransEnterix”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Longevity Health $50,000.00 52.20 -$10.37 million N/A N/A
TransEnterix $8.53 million 2.51 -$154.20 million ($4.22) -0.04

Longevity Health has higher earnings, but lower revenue than TransEnterix.

Volatility and Risk

Longevity Health has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, TransEnterix has a beta of 2.56, indicating that its share price is 156% more volatile than the S&P 500.

Profitability

This table compares Longevity Health and TransEnterix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Longevity Health -682.67% N/A -261.90%
TransEnterix -2,149.15% -83.74% -64.94%

Summary

Longevity Health beats TransEnterix on 6 of the 9 factors compared between the two stocks.

About Longevity Health

(Get Free Report)

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

About TransEnterix

(Get Free Report)

TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.

Receive News & Ratings for Longevity Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longevity Health and related companies with MarketBeat.com's FREE daily email newsletter.